Articles tagged with: Immunotherapy
News»

Good morning, myeloma world.
As we were finalizing today's edition of Myeloma Morning, we were suddenly reminded of how international the field of multiple myeloma research truly is.
The first research study we review below is by a team of German researchers. We also discuss two studies by Korean researchers, and a topic sparked by a report written by Chinese researchers. At the end of today's report, the list of new myeloma research articles also includes publications by investigators in India, Israel, Italy, and the United States.
As we …
News»

There was an important multiple myeloma-related presentation this Monday at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.
The presentation summarized early results of a pilot clinical trial being conducted at the University of Pennsylvania. The trial, which is scheduled to enroll 10 relapsed myeloma patients, is testing a promising approach to cancer treatment known as “chimeric antigen receptor” (CAR) T-cell therapy.
CAR T-cell therapy has generated impressive results when used to treat certain kinds of leukemia and lymphoma. These results have led to a concerted effort to use …
News»

The 51st annual meeting of the American Society of Clinical Oncology (ASCO) started earlier today, May 29, and will go through June 2 in Chicago.
Approximately 30,000 physicians and researchers from all over the world are expected to attend the five-day meeting to discuss current research in cancer treatment and care.
During the meeting, there will be presentations about all types of cancer, including many presentations focused specifically on multiple myeloma. In fact, more than 90 myeloma-related studies are scheduled to be presented, in one form or another, in connection with the …
News, Opinion»

The 2014 International Myeloma Working Group (IMWG) Annual Summit took place in Milan, Italy on June 9 and 10.
The summit is a special meeting organized by the International Myeloma Foundation in which leading myeloma researchers get to brainstorm collectively about the most pressing issues in the field, find ways to collaborate, and plan future laboratory and clinical studies.
The IMWG summit is hailed by most attendees as the most important meeting for myeloma researchers worldwide. It is a unique opportunity for investigators in the field to engage in lively debate but, …
News»

As The Beacon continues its ‘ASH Preview’ series about myeloma research that will be presented at the American Society of Hematology (ASH) meeting in early December, this article focuses on novel immunotherapy approaches that are being studied in clinical trials.
Abstracts for the ASH presentations are now available, although many contain preliminary information that will be updated at the meeting.
The Beacon’s ASH preview articles are intended to highlight the meeting’s most interesting myeloma-related studies.
The first several of the preview articles, which were published over the past …
News»

Findings from a recent Phase 2 clinical study of a multiple myeloma vaccine indicate that the vaccine deepens responses following autologous stem cell transplantation.
Almost half of the patients in the trial achieved a complete response and almost another third achieved a very good partial response after vaccination.
The investigators state that these response rates compare favorably to initial therapy with Revlimid (lenalidomide) or Velcade (bortezomib) followed by stem cell transplantation.
Based on their results, the researchers believe the vaccine used in this trial may be beneficial for …
News»

In a recent review article published in the journal Clinical Cancer Research, two myeloma experts from the Dana-Farber Cancer Institute, Dr. Nikhil Munshi and Dr. Kenneth Anderson, review the latest strategies in the treatment of multiple myeloma.
In their article, the experts discuss newer therapies that appear to be promising in clinical and preclinical studies.
According to the physicians, combination therapies that specifically target a patient’s genetic form of the disease will be required for long-term disease control and ultimately a cure.
Some Historical Perspective
In their review article, Drs. Munshi and …